Government-Owned Inventions; Availability for Licensing, 58288-58289 [2021-22918]
Download as PDF
<![CDATA[
58288
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Notices
MSC 7892, Bethesda, MD 20892, 301 435–
2514, riverase@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 18, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22964 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
jspears on DSK121TN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Government-Owned Inventions;
Availability for Licensing
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
BRAIN Initiative: Kirschstein NRSA
Individual Postdoctoral Fellowships (F32).
Date: November 23, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Jasenka Borzan, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Mental Health, 6001 Executive Blvd.,
Neuroscience Center, Room 6150, Bethesda,
MD 20892, 301–435–1260, jasenka.borzan@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Name of Committee: National Institute on
Aging Special Emphasis Panel; MultiComponent Project.
Date: November 9, 2021.
Time: 1:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Dario Dieguez, Jr., Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, National
Institutes of Health, Gateway Building, Suite
2W200, 7201 Wisconsin Avenue, Bethesda,
MD 20892, (301) 827–3101, dario.dieguez@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Infrastructure
Development for Aging Studies.
Date: November 12, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Isis S. Mikhail, MD, MPH,
DrPH, Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, Gateway
Building 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20892, (301) 402–7704,
mikhaili@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: October 18, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: October 18, 2021.
Miguelina Perez,
Program Analyst Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22966 Filed 10–20–21; 8:45 am]
[FR Doc. 2021–22990 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:35 Oct 20, 2021
Jkt 256001
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications related to this invention.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Novel VAR2CSA Immunogens and
Methods of Use Thereof
Description of Technology
The invention provides immunogen
polypeptides comprising fragments of
VAR2CSA protein expressed by P.
falciparum as potential secondgeneration placental malaria vaccine
candidates. VAR2CSA is the leading
antigen target for a placental malaria
vaccine, where associated antibody
titers are correlated with protection.
Aspects of the inventive immunogen
polypeptides comprise all or portions of
the chondroitin sulfate A (CSA) binding
regions of VAR2CSA, as identified by a
structural study of VAR2CSA conducted
by the inventors, that possess great
sequence conservation among P.
falciparum strains when compared to
competing clinical vaccine candidates
PRIMVAC and PAMVAC. Also provided
are methods of using the immunogen
polypeptides for vaccination and
treatment of disease.
E:\FR\FM\21OCN1.SGM
21OCN1
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Notices
Oncology Application
The VAR2CSA immunogens bind to
oncofetal CSA, a putative therapeutic
target for multiple cancers, including
NSCLC, breast, bladder and 40–50% of
all pediatric solid tumors. Oncofetal
CSA is only expressed solely in the
placenta, except in several cancerous
tissues, making it an ideal target for
targeted therapeutics such as
immunogens that are cross linked to
cytotoxic agents.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Placental malaria vaccine
• CSA-binding proteins for cancer
therapeutics
Competitive Advantages:
• Strain-transcending immunogens for
vaccination
• Improved immunogen production
through expression of key protein
regions
Development Stage:
• Immunogens successfully tested in
a small animal model
jspears on DSK121TN23PROD with NOTICES1
Inventors: Dr. Niraj Tolia and Dr. Rui
Ma, both of NIAID.
Publications: Ma, R. et al., ‘‘Structural
basis for placental malaria mediated by
Plasmodium falciparum VAR2CSA’’,
Nat Microbiol 6, 380–391, 2021.
Intellectual Property: HHS Reference
No. E–021–2021–0–US–01—U.S.
Provisional Application No. 63/115,729,
filed November 19, 2020.
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the invention. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483;
peter.tung@nih.gov.
Dated: October 15, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–22918 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:35 Oct 20, 2021
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Limited Interaction Targeted
Epidemiology (LITE–2): To Advance HIV
Prevention (UG3/UH3 Clinical Trial
Optional).
Date: November 17, 2021.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Kristina S. Wickham,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20852, 301–761–5390,
kristina.wickham@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 15, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22953 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
58289
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Institutional
Training Grants I.
Date: November 2, 2021.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3400 Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ashley Fortress, Ph.D.,
Designated Federal Official, Division of
Extramural Activities, National Eye Institute,
National Institutes of Health, 6700B
Rockledge Drive, Suite 3400, Bethesda, MD
20892, (301) 451–2020, ashley.fortress@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: October 15, 2021.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22919 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
E:\FR\FM\21OCN1.SGM
21OCN1
]]>Agencies
[Federal Register Volume 86, Number 201 (Thursday, October 21, 2021)]
[Notices]
[Pages 58288-58289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-22918]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to this invention.
SUPPLEMENTARY INFORMATION: Technology description follows.
Novel VAR2CSA Immunogens and Methods of Use Thereof
Description of Technology
The invention provides immunogen polypeptides comprising fragments
of VAR2CSA protein expressed by P. falciparum as potential second-
generation placental malaria vaccine candidates. VAR2CSA is the leading
antigen target for a placental malaria vaccine, where associated
antibody titers are correlated with protection. Aspects of the
inventive immunogen polypeptides comprise all or portions of the
chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified
by a structural study of VAR2CSA conducted by the inventors, that
possess great sequence conservation among P. falciparum strains when
compared to competing clinical vaccine candidates PRIMVAC and PAMVAC.
Also provided are methods of using the immunogen polypeptides for
vaccination and treatment of disease.
[[Page 58289]]
Oncology Application
The VAR2CSA immunogens bind to oncofetal CSA, a putative
therapeutic target for multiple cancers, including NSCLC, breast,
bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only
expressed solely in the placenta, except in several cancerous tissues,
making it an ideal target for targeted therapeutics such as immunogens
that are cross linked to cytotoxic agents.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Placental malaria vaccine
CSA-binding proteins for cancer therapeutics
Competitive Advantages:
Strain-transcending immunogens for vaccination
Improved immunogen production through expression of key
protein regions
Development Stage:
Immunogens successfully tested in a small animal model
Inventors: Dr. Niraj Tolia and Dr. Rui Ma, both of NIAID.
Publications: Ma, R. et al., ``Structural basis for placental
malaria mediated by Plasmodium falciparum VAR2CSA'', Nat Microbiol 6,
380-391, 2021.
Intellectual Property: HHS Reference No. E-021-2021-0-US-01--U.S.
Provisional Application No. 63/115,729, filed November 19, 2020.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or [email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483;
[email protected].
Dated: October 15, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-22918 Filed 10-20-21; 8:45 am]
BILLING CODE 4140-01-P
